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Background: In spite of the high prevalence of allergic rhinitis (AR) and the evidence-based guidelines for
treatment, little is known about the patients’ perceived knowledge level, expectations, preferences for treatment,
and fear for side effects of treatment for AR. This study aimed at gaining insight into these patient-related factors.
Methods: This explorative cross-sectional survey study included a convenience sample of 170 patients with rhinitis
and clinical suspicion of allergy at the department of Otorhinolaryngology and Allergology. Patients’ perceived
knowledge level, expectations, patient preferences, and fear of side effects of allergy treatment were collected via a
self-report questionnaire developed for the purpose of this study.
Results: 22% of all patients (38/170) reported to have knowledge about anti-allergic treatment. 40% (55/170) of
rhinitis patients expected to be cured by the prescribed treatment, whereas 43% (73/170) of patients expected
suppression of allergic symptoms. Nasal spray was the preferred route of anti-allergic drug administration in 30%
(52/170) of patients, followed by oral treatment (24%; 42/170), combination therapy (16%; 30/170), and injection
therapy (15%; 27/170). More patients would choose a combination treatment with step-down approach
(31%; 53/170) than mono-therapy with a step-up approach (20%; 34/170). Fear for side effects was reported mainly
for nasal corticosteroids (48%; 81/170) and less for oral antihistamines (33%; 36/170), leucotriene antagonists
(21%, 36/170) and immunotherapy (19%, 33/170).
Conclusions: Patients consulting for rhinitis have high expectations of anti-allergic treatment, prefer a nasal spray
above oral treatment, prefer combined treatment rather than monotherapy, and fear adverse events of anti-allergic
treatment.
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Allergic rhinitis (AR) represents a common airway disease,
with an estimated prevalence of 30% of the total popula-
tion in Europe and the US suffering from allergen-induced
nasal obstruction, rhinorrhoea, sneezing, itchy nose and/
or itchy eyes (1) (2). Thanks to the expansion of studies
on treatment of allergic disease during the last decades,
evidence-based guidelines for treatment of AR are now-
adays available(1). The ARIA document provides an* Correspondence: Peter.Hellings@uzleuven.be
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reproduction in any medium, provided the orextensive overview on clinical effectiveness of available
treatment options. It is however, recommended that clini-
cians tailor their treatment to the individual patient. More
specifically, disease-related aspects of AR like severity of
symptoms and presence of ocular symptoms and co-
morbidities need to be taken into consideration, besides
drug-related features like efficacy, route of administration
and cost-efficacy. Additional considerations at the time of
prescribing a treatment relate to the choice for mono-
therapy versus combination treatment, nasal or oral route
of drug delivery and planning of immunotherapy. Ideally,
patient’s expectations, preferences and possible fear for
side effects of the different treatment options should be
assessed and taken into consideration in the choice ofal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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may not be superior to the other in view of clinical effi-
cacy. However, patients’ expectations, preferences for
treatment and approach, and fear of side-effects patients
are often neglected in this medical decision-making pro-
cesses, in spite of the fact that these patients’ factors are
an important determinant of patients' adherence and per-
sistence to treatment (3) (4).
Evidence shows that a substantial proportion of patients
with AR seem to have a clear idea about their preferred
treatment for AR and visit a doctor solely to get a pre-
scription (5). The role of patients’ views on disease and
treatment is illustrated by a recent large-scale European
survey among AR patients (5). This study highlighted sev-
eral reasons for under-diagnosis and under-treatment:
patients state that their condition is not severe enough to
warrant medication, they do not feel that the allergy medi-
cation would be effective for their symptoms, they suffer
from side-effects of the medication, and/or they believe
that anti-allergic medications are habit-forming. These
perceptions towards medical treatment may largely inter-
fere with the control of disease, especially in regard to
non-adherence and non-persistence.
At present, very little is known about patients’ perceived
level of knowledge, expectations of treatment, preferences
and fear for side effects for the different treatment modal-
ities for AR. This cross-sectional explorative study there-
fore aims at investigating these patient-related factors in
AR management, which has been a neglected area of re-
search so far. In addition, this study also aims at exploring
differences of these factors between genders and among
patients with different educational levels, as the impact of
these factors is unknown.
Methods
Design, sample and setting
This explorative cross-sectional study was conducted be-
tween July and December 2008 at the Ear, Nose and
Throat Unit and Allergology Department of the Univer-
sity Hospitals of Leuven, Belgium. A convenience sample
of 170 adult patients between 18 and 60 years of age vis-
iting the outpatient clinic with rhinitis, without clinical
evidence of rhinosinusitis after nasal endoscopy and pro-
viding written informed consent, was included in this
study. Non-Dutch speaking patients were excluded, as
well as patients with previous allergy testing and hence
known sensitization state, as well as patients on current
oral antihistamine treatment in which skin prick tests
(SPT) were not performed. Patients were asked to fill in
the questionnaire prior to performing the SPT, and thus
were not aware of the outcome of the test when filling
out the questionnaire. The study protocol was approved
by the ethical committee of the University Hospitals of
Leuven.SPT were performed by trained personnel and involved
the most prevalent inhalant allergens in Belgium (house
dust mites, grass pollen, tree pollen and animal dander,
Alternaria, Penicillium and Cladosporium, (Hal Allergy,
Leiden, The Netherlands)). A SPT was defined positive by
a wheal reaction of at least 3 mm in diameter or of a size
equal to or larger than the positive control after 15 min-
utes. The diagnosis of AR was based on the ARIA criteria,
involving 2 or more nasal symptoms associated with AR,
and demonstration of sensitization by a positive SPT
result.Variables and measurement
The self-report questionnaire used in this study consisted
of a total of 12 items and was developed specifically for
this study. The questionnaire assessed demographic and
clinical variables, perceived level of knowledge, expecta-
tions of treatment, preferences in view of treatment and
fear of side effects of the most common treatment options
for AR. The development of the questionnaire was based
on the clinical experience of the P.I. of this study (P.H.).
The following demographic variables were assessed: age
(in years), gender (male/female), highest level of education
(i.e. university, postgraduate eduction, high school, tech-
nical education and primary school). The clinical variable
assessed was previous anti-allergic treatment (yes/no).
Perceived level of knowledge was assessed by one item.
Patients were asked if they perceived themselves as hav-
ing knowledge about anti-allergic treatment prior to the
outpatient clinic visit (yes/no).
Expectations of anti-allergic treatment was assessed by
one item. Patients were asked to indicate what their ex-
pectation of treatment was, i.e. suppression of symp-
toms, cure from allergic rhinitis, combination of both
previous options, none of the previous options, or no
opinion.
Fear of adverse events was evaluated by 4 items.
Patients were asked to indicate for each of the 4 most
frequently prescribed anti-allergic treatment options, i.e.
nasal corticosteroid spray, oral antihistamine tablet, oral
leukotriene antagonist tablet, and immunotherapy, if
they feared adverse effects (yes/no/no opinion). Patients
were provided with an option for free text to specify
which adverse effects they feared for each of these
treatments.Data collection and analysis
As indicated above data collection took place during a
regular outpatient clinic appointment. Patients were invited
by P.H. to participate in the study before the SPT was per-
formed. After obtaining informed consent, patients filled
out the questionnaires. Two investigators (V.A. and P.H.)
checked completeness of the returned questionnaires.
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ard deviations, medians/interquartile ranges as appropriate
based on measurement level and distribution of the vari-
able. Inferential statistics used were Fisher’s exact test.
Statistical significance was set at 0.05.
Results
Study population
The total number of rhinitis patients included in this ana-
lysis was 170 with a balanced male/female ratio (84/86), and
mean age of 40 years of age (SD: 15). SPT were performed
in case of clinical suspicion of underlying sensitization. 42%
(72/170) had positive SPT results, with the remaining 58%
(98/170) being diagnosed as non-allergic rhinitis.Figure 1 Percentages of patients reporting knowledge about allergic
to previous treatment for allergic rhinitis (B), to highest educational lPerceived knowledge regarding anti-allergic treatment
Overall, 38 out of 170 rhinitis patients (22%) with suspicion
of AR indicated to have knowledge about allergy treatment.
A higher percentage of patients with a positive SPT (30%;
22/72) reported knowledge on allergy treatment than
patients with negative SPT (15%; 16/98, Figure 1A;
p=0.04). Not unexpectedly, patients who had been treated
in the past for allergic rhinitis reported more frequently
(31%; 24/77, Figure 1B; p=0.009) they had knowledge on
AR treatment than patients without previous anti-allergic
treatment (Figure 1B). 43% of patients with university edu-
cation reported knowledge with AR treatment contrasted
with the 20% of patients with less then university education
reporting knowledge with ART (Figure 1C; p= 0.0006)).treatment, in relation to SPT results (negative, - vs positive, +, A),
evel (C), and to gender (D).
Hellings et al. Clinical and Translational Allergy 2012, 2:9 Page 4 of 8
http://www.ctajournal.com/content/2/1/9Female patients reported higher knowledge with AR treat-
ment (30%; 26/86) compared to male patients (14%; 12/84,
Figure 1D; p=0.02).
Expectations in view of anti-allergic treatment
When asked about expectations regarding allergy treat-
ment, 43% (73/170) expected a suppression of allergy
symptoms, 12% (21/170) expected to be cured from their
allergy, and 20% (34/170) expected both suppression of

















Figure 2 Patients’ expectations on anti-allergic treatment, in relation
of patients expecting suppression, cure, combination of both, none of bothsignificantly between patients with and without positive
SPT (Figure 2A), nor between genders (Figure 2B;
p = 0.06).
Patients' preference for treatment modality and strategy
for AR
Concerning the preferred route of treatment for AR
(Figure 3A), 30% (52/170) preferred a nasal spray, 25%
(42/170) preferred oral treatment and 16% (30/170) pre-















to SPT results (A) and gender (B). Data are expressed in percentages
, no opinion or unspecified.
Figure 3 Patients’ preferred approach for anti-allergic treatment in rhinitis. Patients’ preference on treatment for AR: either a nasal spray,
oral tablet, combination of both, injection treatment, none of previous or other treament (A). Patients’ preferred strategy of treatment with either
step up or step down in relation to symptom control (B).
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rarely marked (Figure 3A).
When being asked about the preferred medical approach,
46% (78/170) of patients marked no opinion (Figure 3B).
Thirty-three percent (53/170) preferred to start with a
combination therapy followed by step-down, while 20%
(34/170) of patients preferred the gradual step-up treatment
from monotherapy until complaints are completely under
control. Three percent of patients did not answer this ques-
tion (5/170).
Fear of side effects of anti-allergic therapy
Concerning nasal corticosteroid sprays, 48% (81/170)
expressed concerns in view of side effects of this treatment
(Figure 4). Thirty three percent of patients (56/170) feared
side effects of oral antihistamines, 20% (36/170) did so for
leukotriene antagonists, and 19% (33/170) feared side
effects of immunotherapy.
Table 1 and 2 provide more detailed information what
kind of specific side effects where feared by patients in the
light of the nasal corticoisteroids and oral antihistamines
respectively. Specific adverse events of leukotriene antago-
nists or immunotherapy were only mentioned by a neglect-
able percentage of patients (2% (3/170) and 3% (5/170)
respectively) and therefore not reported.
Discussion
This explorative cross-sectional study focuses on relevant
patient reported outcomes in view of medical treatment
for AR. More specifically, patients' perceived knowledge,
expectations, preferences, and fear for side effects of AR
treatment were studied. Patient’s beliefs and attitudes are
important drivers in health behaviour including medication
nonadherence and poor persistence in chronically ill pa-
tient populations (6,7). Also fear of side effects hinders
patient’s engaging in prescribed treatment. So far, theseFigure 4 Percentage of total patients marking fear for adverse events
leukotriene antagonists and immunotherapy, no fear or no opinion.factors have been underinvestigated in AR although we
can infer from empirical evidence of other chronically ill
patient groups that they influence patients’ motivation to
start medical treatment and the impact of these factors on
patients’ adherence and persistence to treatment. The latter
factors are however considered to be of utmost importance
in disease control (8).
Our findings show that 22% of patients presenting
with rhinitis at ourn outpatient visit report some know-
ledge on anti-allergic treatment. These data strengthen
therefore clinicians’ perceptions that a substantial pro-
portion of patients already have some knowledge on the
treatment of the disease. The perceived level of know-
ledge was highest in those who were treated previously,
in patients with the highest educational level and in
females. However, the correctness of this knowledge al-
ways needs to be checked in patients, irrespective of educa-
tional level or gender, as their knowledge about anti-allergic
treatment may not be perfect. Indeed, the knowledge on
anti-allergic treatment is often incorrect in Europe, as
demonstrated by a large-scale survey. Maurer et al. studied
the problem of underdiagnosis and undertreatment of
patients with AR in Europe (5), demonstrating the presence
of several false beliefs of patients on anti-allergic therapy like
lack of availability of effective medical treatment and habit-
forming effect of anti-allergic therapy.
It had been demonstrated before that patients with AR
have a low level of satisfaction with their treatment for AR
(9). This is not a surprise in the light of the current data
showing high expectations of anti-allergic treatment. A
large portion of patients expected to be cured from their
allergy, or to have suppression of their complaints. Interest-
ingly, there seem to be subtle differences in gender when it
comes to expectations of anti-allergic treatment. More
men expected an actual cure for their disease, whereas
women tended to more frequently expect a suppression oflinked to nasal corticosteroid spray, oral antihistamines, oral
Table 1 List of specific fears for adverse events of nasal
corticosteroid sprays mentioned by rhinitis patients
Fear for adverse events of nasal corticosteroid spray (N = 24)
Habituation 7/24 (29%)
Damage to mucous membranes 6/24 (25%)
Influence on other organs like heart, eyes, skin 6/24 (25%)
Addiction 4/24 (17%)
Weakened resistance to infection 3/24 (12%)
Weight gain 1/24 (4%)
Cancer development 1/24 (4%)
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vations is to clearly discuss with the patient the goal of
treatment of AR, albeit symptom reduction by medical
treatment or alteration of the immune system and hence
cure by immunotherapy. Therefore, it seems important to
address unrealistic expectations in patients by explaining
the underlying etiology, mechanisms and aims of anti-
allergic treatment.
Concerning the way of treatment for AR, a nasal spray
was preferred above oral treatment, combination treatment
and injection therapy (Figure 3A). Therefore, treating the
affected organ in AR seemed for most patients the pre-
ferred medical approach in AR. The anti-allergic treatment
as combined treatment, with step down to monotherapy at
the time of symptom control, was preferred over mono-
therapy with eventual combination treatment at the time
of insufficient symptom control with monotherapy. This
patient preference might be influenced by the severity of
the symptoms, previous treatment experience, and type of
medical center. Being a tertiary referral center, the major-
ity of patients included in this trial were at the most severe
spectrum of allergic disease, i.e. moderate to severe per-
sistent allergic rhinitis, explaining in part why mostTable 2 List of specific fears for adverse events of oral
antihistamines mentioned by rhinitis patients




Gastric ulcer 1/28 (4%)
Interactions with other drugs 1/28 (4%)
Thirst 1/28 (4%)
Dry throat 1/28 (4%)
Dry eyes 1/28 (4%)
Fever, rash 1/28 (4%)
Addiction 1/28 (4%)
Weight increase 1/28 (4%)patients would chose a combination treatment rather than
monotherapy.
In spite of the availability of novel corticosteroids with
low bioavailability, high receptor specificity and selectivity,
there still exists a strong prejudice against the use of corti-
costeroids amongst patients (10). We illustrate here that
48% of our study population is concerned about adverse
effects when using a nasal spray containing corticoster-
oids. The adverse events associated with nasal corticoster-
oid treatment ranged from habituation, to local damage to
systemic adverse events. A similar fear for side effects was
reported for oral treatment with antihistamines, but there
appears to be more confidence since only 33% expressed
their concern about the presence of fatigue as major side
effect. Indeed, fatigue was a common adverse events in the
first generation anti-histamines, but is no longer an issue
in the newer second generation antihistamines. Taken to-
gether the large portion of patients fearing adverse events,
medical doctors treating patients with AR should have a
clear view on the potential adverse events of any of the
prescribed drugs for AR and discuss with these with
patients the unrealistic fear for adverse events. Concerning
leukotriene receptor antagonists and immunotherapy, the
patient does not seem to fear these options as much as the
latter, without specification of adverse events. We estimate
that the latter two treatment options are less well known
amongst the general popultion, explaining the lack of fear
of adverse events in most rhinitis patients.
As in every observational study, some methodological
shortcomings are present. First, we only enrolled a highly
selected group of patients consulting a tertiary care center
for diagnosis and treatment. It remains unclear if know-
ledge and patient preferences would be similar in other
healthcare settings, e.g. primary care. Moreover, about 42%
of the study population had positive SPT results, revealing
a higher percentage of allergic disease in the patients con-
sulting the department of Otorhinolaryngology and Aller-
gology than in the general population (1), relfecting a
referal bias. Given the fact that the SPT results were not
disclosed to patients at the time of completion of the ques-
tionnaire and knowledge levels were not different between
those patients with and without positive SPT results, we
decided not to omit the information obtained in the
patients with non-allergic rhinitis. For the sake of clarity,
we have chosen to limit the questionnaire to the most rele-
vant questions on anti-allergic treatment involving the most
commonly prescribed medical approaches.
In spite of the shortcomings, the results of the present
study have some important clinical implications. The ul-
timate goal of any medical treatment is to fully control
symptoms and improve quality of life in affected patients.
Involving patients in the decision process regarding their
treatment may enhance their self-care commitment and
hence increase therapeutic adherence and efficiency. In
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opinion into account increases therapeutic adherence (11)
and patients' satisfaction with treatment. However, clinical
reality often learns that patients are ill-informed, and may
have false expectations and prejudices about anti-allergic
therapy. It remains to be determined if investment in bet-
ter support for patient self management and incorporating
the patients’ view on disease and treatment will indeed re-
sult in better adherence, persistence of treatment and
improved patient satisfaction.
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